EFFECTS OF ADHERENCE TO PHARMACOLOGICAL SECONDARY PREVENTION AFTER MYOCARDIAL INFARCTION ON HEALTHCARE EXPENDITURES

Author(s)

Kirsch F1, Becker C2, Maier W2, Schramm A3
1Ludwig-Maximilians-University Munich, Munich, Germany, 2HelmholtzZentrum Munich, Neuherberg, Germany, 3AOK Bayern, Regensburg, Germany

Presentation Documents

OBJECTIVES:

Following acute myocardial infarction (AMI) patients are at increased risk of mortality, morbidity, and excess costs. Current guidelines recommend using anti-platelet agents, statins, β-blockers, and angiotensin-converting enzyme inhibitors for secondary prevention after AMI. Non-adherence to medication is considered a major health policy issue, accounting for a considerable worsening of the disease, poor prognosis, death, and increased healthcare costs

Conference/Value in Health Info

2017-11, ISPOR Europe 2017, Glasgow, Scotland

Value in Health, Vol. 20, No. 9 (October 2017)

Code

PCV49

Topic

Economic Evaluation

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis

Disease

Cardiovascular Disorders

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×